[{"address1": "260 Littlefield Avenue", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 481 6770", "website": "https://pliantrx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of av\u00df6 and av\u00df1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of av\u00df1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins av\u00df8 and av\u00df1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.", "fullTimeEmployees": 166, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bernard  Coulie M.B.A., M.D., Ph.D.", "age": 56, "title": "President, CEO & Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 996968, "exercisedValue": 5432729, "unexercisedValue": 7282323}, {"maxAge": 1, "name": "Dr. Keith Lamont Cummings M.B.A., M.D.", "age": 46, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 684144, "exercisedValue": 1694253, "unexercisedValue": 2111570}, {"maxAge": 1, "name": "Mr. Mike  Ouimette J.D.", "age": 50, "title": "General Counsel & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 606028, "exercisedValue": 322078, "unexercisedValue": 198044}, {"maxAge": 1, "name": "Mr. Johannes P. Hull", "age": 48, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 602513, "exercisedValue": 189873, "unexercisedValue": 1831996}, {"maxAge": 1, "name": "Dr. Eric A. Lefebvre M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 734411, "exercisedValue": 0, "unexercisedValue": 2070744}, {"maxAge": 1, "name": "Dr. Rik  Derynck", "title": "Scientific Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dean  Sheppard M.D.", "title": "Scientific Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bill  DeGrado Ph.D.", "title": "Scientific Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Hal  Chapman M.D.", "title": "Scientific Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Craig D. Muir", "title": "Interim Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 12.82, "open": 12.86, "dayLow": 12.63, "dayHigh": 13.46, "regularMarketPreviousClose": 12.82, "regularMarketOpen": 12.86, "regularMarketDayLow": 12.63, "regularMarketDayHigh": 13.46, "beta": 1.151, "forwardPE": -3.2962961, "volume": 246268, "regularMarketVolume": 246268, "averageVolume": 547056, "averageVolume10days": 261470, "averageDailyVolume10Day": 261470, "bid": 13.31, "ask": 13.38, "bidSize": 200, "askSize": 400, "marketCap": 811698688, "fiftyTwoWeekLow": 10.29, "fiftyTwoWeekHigh": 19.62, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 12.5214, "twoHundredDayAverage": 14.3303, "currency": "USD", "enterpriseValue": 403093280, "floatShares": 49874801, "sharesOutstanding": 60801400, "sharesShort": 7339293, "sharesShortPriorMonth": 6958605, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.120699994, "heldPercentInsiders": 0.02861, "heldPercentInstitutions": 1.12433, "shortRatio": 13.45, "shortPercentOfFloat": 0.1233, "bookValue": 6.499, "priceToBook": 2.0541623, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -185404992, "trailingEps": -3.09, "forwardEps": -4.05, "enterpriseToEbitda": -1.96, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "PLRX", "underlyingSymbol": "PLRX", "shortName": "Pliant Therapeutics, Inc.", "longName": "Pliant Therapeutics, Inc.", "firstTradeDateEpochUtc": 1591191000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2b91961b-ace6-3459-85c8-5f512c816863", "gmtOffSetMilliseconds": -14400000, "currentPrice": 13.35, "targetHighPrice": 47.0, "targetLowPrice": 32.0, "targetMeanPrice": 41.36, "targetMedianPrice": 41.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 436607008, "totalCashPerShare": 7.181, "ebitda": -205706000, "totalDebt": 60226000, "quickRatio": 14.209, "currentRatio": 14.473, "debtToEquity": 15.337, "returnOnAssets": -0.24531001, "returnOnEquity": -0.40055, "freeCashflow": -88957376, "operatingCashflow": -136894000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]